| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | dabrafenib | CTRPv2 | pan-cancer | AAC | 0.43 | 9e-15 |
| mRNA | dabrafenib | GDSC1000 | pan-cancer | AAC | 0.27 | 1e-11 |
| mRNA | PD-0325901 | GDSC1000 | pan-cancer | AAC | 0.26 | 5e-10 |
| mRNA | GDC-0879 | CTRPv2 | pan-cancer | AAC | 0.28 | 6e-10 |
| mRNA | PLX4720 | CTRPv2 | pan-cancer | AAC | 0.28 | 2e-09 |
| mRNA | PLX4720 | GDSC1000 | pan-cancer | AAC | 0.24 | 2e-09 |
| mRNA | PLX4720 | CCLE | pan-cancer | AAC | 0.4 | 3e-09 |
| mRNA | selumetinib:PLX-4032 (8:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.27 | 9e-09 |
| mRNA | (5Z)-7-Oxozeaenol | GDSC1000 | pan-cancer | AAC | 0.22 | 6e-08 |
| mRNA | PD-0325901 | CCLE | pan-cancer | AAC | 0.35 | 8e-08 |